MedKoo Biosciences, Inc.
Tel:   +1-919-636-5577    Fax:   +1-919-980-4831    Email:   sales@medkoo.com
Search
Login Register
Search
MedKoo Cat#: 555853 | Name: DZ2002

Description:

WARNING: This product is for research use only, not for human or veterinary use.

DZ-2002 is a potent reversible inhibitor of S-adenosyl-L-homocysteine hydrolase (SAHH). DZ2002 ameliorates fibrosis, inflammation, and vasculopathy in experimental systemic sclerosis models. DZ2002 prevents the development of experimental dermal fibrosis by reversing the profibrotic phenotype of various cell types and would be a potential drug for the treatment of systemic sclerosis.

Chemical Structure

DZ2002
DZ2002
CAS#33231-14-0

Theoretical Analysis

MedKoo Cat#: 555853

Name: DZ2002

CAS#: 33231-14-0

Chemical Formula: C10H13N5O3

Exact Mass: 251.1018

Molecular Weight: 251.25

Elemental Analysis: C, 47.81; H, 5.22; N, 27.88; O, 19.10

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.
Bulk Inquiry
Related CAS #
No Data
Synonym
DZ-2002; DZ 2002; DZ2002;
IUPAC/Chemical Name
9H-Purine-9-butyric acid, 6-amino-alpha-hydroxy-, methyl ester
InChi Key
HNKGMGPCSSJYOT-UHFFFAOYSA-N
InChi Code
InChI=1S/C10H13N5O3/c1-18-10(17)6(16)2-3-15-5-14-7-8(11)12-4-13-9(7)15/h4-6,16H,2-3H2,1H3,(H2,11,12,13)
SMILES Code
O=C(OC)C(O)CCN1C=NC2=C(N)N=CN=C12
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>3 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info

Preparing Stock Solutions

The following data is based on the product molecular weight 251.25 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
1: Zhang Z, Wu Y, Wu B, Qi Q, Li H, Lu H, Fan C, Feng C, Zuo J, Niu L, Tang W. DZ2002 ameliorates fibrosis, inflammation, and vasculopathy in experimental systemic sclerosis models. Arthritis Res Ther. 2019 Dec 16;21(1):290. doi: 10.1186/s13075-019-2074-9. PMID: 31842999; PMCID: PMC6916442. 2: Jia W, Li J, Du F, Sun Y, Xu F, Wang F, Olaleye OE, Chen D, Tang W, Zuo J, Li C. Assay development for determination of DZ2002, a new reversible SAHH inhibitor, and its acid metabolite DZA in blood and application to rat pharmacokinetic study. J Pharm Anal. 2019 Feb;9(1):25-33. doi: 10.1016/j.jpha.2018.09.001. Epub 2018 Sep 7. PMID: 30740254; PMCID: PMC6355468. 3: He S, Liu X, Lin Z, Liu Y, Gu L, Zhou H, Tang W, Zuo J. Reversible SAHH inhibitor protects against glomerulonephritis in lupus-prone mice by downregulating renal α-actinin-4 expression and stabilizing integrin- cytoskeleton linkage. Arthritis Res Ther. 2019 Jan 29;21(1):40. doi: 10.1186/s13075-019-1820-3. PMID: 30696480; PMCID: PMC6352376. 4: Lin ZM, Ma M, Li H, Qi Q, Liu YT, Yan YX, Shen YF, Yang XQ, Zhu FH, He SJ, Tang W, Zuo JP. Topical administration of reversible SAHH inhibitor ameliorates imiquimod-induced psoriasis-like skin lesions in mice via suppression of TNF-α/IFN-γ-induced inflammatory response in keratinocytes and T cell-derived IL-17. Pharmacol Res. 2018 Mar;129:443-452. doi: 10.1016/j.phrs.2017.11.012. Epub 2017 Nov 14. PMID: 29155016. 5: He SJ, Lin ZM, Wu YW, Bai BX, Yang XQ, He PL, Zhu FH, Tang W, Zuo JP. Therapeutic effects of DZ2002, a reversible SAHH inhibitor, on lupus-prone NZB×NZW F1 mice via interference with TLR-mediated APC response. Acta Pharmacol Sin. 2014 Feb;35(2):219-29. doi: 10.1038/aps.2013.167. Epub 2013 Dec 30. PMID: 24374810; PMCID: PMC4651227. 6: Tardif V, Manenkova Y, Berger M, Hoebe K, Zuo JP, Yuan C, Kono DH, Theofilopoulos AN, Lawson BR. Critical role of transmethylation in TLR signaling and systemic lupus erythematosus. Clin Immunol. 2013 May;147(2):133-43. doi: 10.1016/j.clim.2013.02.018. Epub 2013 Mar 5. PMID: 23583916; PMCID: PMC3634912. 7: Kominsky DJ, Keely S, MacManus CF, Glover LE, Scully M, Collins CB, Bowers BE, Campbell EL, Colgan SP. An endogenously anti-inflammatory role for methylation in mucosal inflammation identified through metabolite profiling. J Immunol. 2011 Jun 1;186(11):6505-14. doi: 10.4049/jimmunol.1002805. Epub 2011 Apr 22. PMID: 21515785; PMCID: PMC3383860. 8: Zhang YM, Ding Y, Tang W, Luo W, Gu M, Lu W, Tang J, Zuo JP, Nan FJ. Synthesis and biological evaluation of immunosuppressive agent DZ2002 and its stereoisomers. Bioorg Med Chem. 2008 Oct 15;16(20):9212-6. doi: 10.1016/j.bmc.2008.09.017. Epub 2008 Sep 9. PMID: 18815049. 9: Lawson BR, Manenkova Y, Ahamed J, Chen X, Zou JP, Baccala R, Theofilopoulos AN, Yuan C. Inhibition of transmethylation down-regulates CD4 T cell activation and curtails development of autoimmunity in a model system. J Immunol. 2007 Apr 15;178(8):5366-74. doi: 10.4049/jimmunol.178.8.5366. PMID: 17404322. 10: Fu YF, Zhu YN, Ni J, Zhong XG, Tang W, Re YD, Shi LP, Wan J, Yang YF, Yuan C, Nan FJ, Lawson BR, Zuo JP. A reversible S-adenosyl-L-homocysteine hydrolase inhibitor ameliorates experimental autoimmune encephalomyelitis by inhibiting T cell activation. J Pharmacol Exp Ther. 2006 Nov;319(2):799-808. doi: 10.1124/jpet.106.107185. Epub 2006 Aug 16. PMID: 16914558. 11: Fu YF, Wang JX, Zhao Y, Yang Y, Tang W, Ni J, Zhu YN, Zhou R, He PL, Li C, Li XY, Yang YF, Lawson BR, Zuo JP. S-adenosyl-L-homocysteine hydrolase inactivation curtails ovalbumin-induced immune responses. J Pharmacol Exp Ther. 2006 Mar;316(3):1229-37. doi: 10.1124/jpet.105.093369. Epub 2005 Dec 2. PMID: 16326921. 12: Wu QL, Fu YF, Zhou WL, Wang JX, Feng YH, Liu J, Xu JY, He PL, Zhou R, Tang W, Wang GF, Zhou Y, Yang YF, Ding J, Li XY, Chen XR, Yuan C, Lawson BR, Zuo JP. Inhibition of S-adenosyl-L-homocysteine hydrolase induces immunosuppression. J Pharmacol Exp Ther. 2005 May;313(2):705-11. doi: 10.1124/jpet.104.080416. Epub 2005 Jan 7. PMID: 15640397.